araag2/HINT huggingface dataset:
Clinical trial NCT01321554 (phase 3, status: completed)
Conditions: thyroid cancer
ICD codes: C73, D34, D44.0, Z85.850
Drugs: lenvatinib, placebo, lenvatinib
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion criteria:

          1. Histologically or cytologically confirmed diagnosis of one of the following DTC
             subtypes: Papillary thyroid cancer (PTC) or follicular thyroid cancer (FTC).

          2. Measurable disease according to (RECIST 1.1) and confirmed by central radiographic
             review.

          3. 131 I-refractory/resistant disease.

          4. Evidence of disease progression within 12 months prior to signing informed consent (+1
             month screening window).

          5. Prior treatment with 0 or 1 vascular endothelial growth-factor (VEGF) or vascular
             endothelial growth-factor receptors (VEGFR) targeted therapy.

          6. Adequate renal, liver, bone marrow, and blood coagulation function, as defined in the
             protocol.

        Exclusion criteria:

          1. Anaplastic or medullary carcinoma of the thyroid

          2. 2 or more prior VEGF/ VEGFR-targeted therapies

          3. Received any anticancer treatment within 21 days or any investigational agent within
             30 days prior to the first dose of study drug.

        Inclusion criteria for OOL Lenvatinib Treatment Period :

        Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period
        if the met the following criteria:

          1. Placebo-treated participants in the Randomization Phase who had progressive disease
             (PD) confirmed by IIR, and who requested treatment with lenvatinib.

          2. Participants who continued to satisfy specified inclusion and exclusion criteria as
             presented in the study protocol.

          3. Participants with maximum interval between the day of confirmation of PD by IIR and
             Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period of less than or equal to 3
             months.

          4. No systemic anticancer treatment during the interval between the day of confirmation
             of PD by the IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period.
Clinical trial NCT01224366 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of T2DM

          -  On a stable dose of insulin as defined by the protocol

          -  On a stable does of metformin (if applicable) as defined by the protocol

          -  Age 18 to 80 years

          -  HbA1c of 7.5 to 11.0%

          -  Body Mass Index (BMI) 22 to 40 kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Short-acting or rapid-acting insulin

          -  Pregnancy or lactation

          -  Evidence of serious diabetic complications

          -  Evidence of serious cardiovascular complications

          -  Laboratory value abnormalities as defined by the protocol

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01513473 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin degludec, insulin detemir, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent, and child assent as age-appropriate, obtained before any
             trial-related activities (Trial-related activities are any procedure that would not
             have been performed during normal management of the subject). The parents or legal
             representative of the child must sign and date the Informed Consent Form according to
             local requirements. The child, if possible, parents or legal representative of the
             child must sign and date the Child Assent Form according to local requirements

          -  Male or female diagnosed with type 1 diabetes mellitus (T1DM) (based on clinical
             judgement and supported by laboratory analysis as per local guidelines)

          -  Ongoing daily treatment with insulin (any regimen) for at least 3 months prior to
             Visit 1 (screening). No OADs (oral anti-diabetic drugs) are allowed

          -  HbA1c (glycosylated haemoglobin) maximum 11%

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial product(s) or related products

          -  Previous participation in this trial. Participation is defined as randomisation

          -  Girls who are pregnant, breastfeeding or intend to become pregnant

          -  Girls who have had menarche and are not using adequate contraceptive measures
             according to local requirements

          -  Known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by
             the Investigator (trial physician)

          -  More than 1 diabetic ketoacidosis requiring hospitalisation within the last 3 months
             prior to Visit 1

          -  Significant concomitant disease, except for conditions associated with type 1 diabetes
             mellitus, which in the Investigator's opinion could interfere with the trial

          -  The receipt of any investigational drug within 1 month prior to Visit 1
Clinical trial NCT00099203 (phase 3, status: terminated)
Conditions: pain, bone neoplasm, neoplasm metastasis
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ibandronate [bondronat], zoledronic acid
SMILES: CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients with malignant bone disease;

          -  patients with moderate to severe pain.

        Exclusion Criteria:

          -  patients who have received a bisphosphonate within 3 weeks from the signing of the
             informed consent;

          -  patients receiving concurrent investigational therapy, or who have received
             investigational therapy within 30 days of the first scheduled day of dosing;

          -  untreated esophagitis or gastric ulcers;

          -  recent or pre-scheduled radiotherapy to bone;

          -  patients who are pregnant or breast-feeding.
Clinical trial NCT00528567 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab, standard adjuvant chemotherapy
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  operable primary invasive breast cancer;

          -  completed definitive loco-regional surgery;

          -  primary tumor centrally confirmed as triple negative.

        Exclusion Criteria:

          -  locally advanced breast cancers;

          -  previous breast cancer history;

          -  clinically significant cardiovascular disease.
Clinical trial NCT00429962 (phase 3, status: completed)
Conditions: choroidal neovascularization, age-related macular degeneration
ICD codes: H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211, H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: intravitreal ranibizumab, intravitreal ranibizumab & photodynamic therapy
SMILES: [Cr], COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C
Eligibility criteria:

        Inclusion Criteria:

          1. patients over 50 years, subfoveal CNV of any type secondary to age-related macular
             degeneration (AMD), no "macula-treatment for the last 30 days (e.g. with PDT, TA,
             Laser, Macugen®).

               -  the area of the CNV must occupy at least >50% of the lesion (total lesion size
                  under 5400 microns in greatest linear dimension)

               -  Occult CNV:

                    -  recent disease progression

                    -  bleeding

                    -  VA decreased the last three months >5 letters or 2 or more than two lines
                       (Snellen)

                    -  10% increase of the lesion size the last three months

          2. Best corrected visual acuity score between 24-73 letters (20/40 to 20/320) (ETDRS 4 m)

        Exclusion Criteria:

          1. Prior treatment with mit Laser, PDT, Macugen, TA

          2. Prior treatment with radiatio, vitrectomy, transpupillary thermotherapy

          3. History of surgical intervention in the study eye within two months preceding day 1

          4. concurrent use of systemic anti-VEGF agents

          5. previous treatment with or participation in a clinical trial involving anti-angiogenic
             drugs (Pegaptanib, ranibizumab, anecortave acetate of corticosteroids).

          6. Ocular disorders in the study eye that may confound interpretation of the study
             results, including retinal detachment or macular hole (Stage 3 or 4), active
             intraocular inflammation (grade trace or above) or persistent macular edema due to
             uveitis or other inflammatory diseases

          7. Retinal pigment epithelium tear, vitreous hemorrhage or history of rhegmatogenous
             retinal detachment or macular hole in the study eye

          8. History of idiopathic or autoimmune-associated uveitis in either eye, active
             infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye

          9. Extracapsular extraction of cataract with phacoemulsification within two months
             preceding day 1, or a history of post-operative complications within the last 12
             months preceding day 1 or a history of post-operative complications within the last 12
             months preceding day 1 in the study eye (uveitis, cyclitis, iritis etc.)

         10. Glaucoma with IOP>25 mmHg despite therapy

         11. Aphakia or absence of the posterior capsule in the study eye

         12. Spherical equivalent >-8
Clinical trial NCT00122616 (phase 3, status: completed)
Conditions: hiv infections, hepatitis c, chronic
ICD codes: Z21, B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: ribavirin, hiv antiretroviral therapy, hiv antiretroviral therapy
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  HIV infection (Western Blot +)

          -  C hepatitis (RNA viral hepatitis C [VHC] +)

          -  Chronic active C hepatitis on liver histological score METAVIR (A over or equal to 1
             and F over or equal to 2) on biopsy performed at least 18 months before the expected
             date of inclusion

          -  Previous treatment for C hepatitis for at least 3 months including peg-interferon and
             ribavirin or peg-interferon alone if counterindication for ribavirin occurred

          -  Failure to eradicate C hepatitis virus after well conducted treatment

          -  The liver biopsy should have been realised at least 18 months before inclusion :

        Either before treatment for C hepatitis in patients treated at most 7 months Or at least 6
        months after anti HCV treatment in patient treated for more than 7 months (wash out period)

          -  Regular follow up in an outpatient clinic for HIV

          -  Unchanged antiretroviral treatment the last 3 months before inclusion

          -  Inform consent

        Exclusion Criteria:

          -  History of transplantation or clinical hepatic failure

          -  Opportunistic infection in the past three months before inclusion

          -  Any hepatic disease not related to HCV (B hepatitis, hemochromatosis, Wilson disease)

          -  Diabetes mellitus

          -  Immunocompromised treatment

          -  Active intravenous drug addiction

          -  Alcohol consumption of more than 50 g per day

          -  Counterindication for the use of interferon
Clinical trial NCT00093990 (phase 3, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: tipifarnib;zarnestra; r115777
SMILES: CN1C=NC=C1[C@@](N)(C1=CC=C(Cl)C=C1)C1=CC2=C(C=C1)N(C)C(=O)C=C2C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed or re-lapsing AML

          -  Patient not medically fit for combination induction chemotherapy

          -  Pathologic confirmation of AML (= or > 20% bone marrow leukemic blasts)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

        Exclusion Criteria:

          -  Previous cytotoxic or biologic treatment for AML

          -  Acute promyelocytic leukemia (APL)

          -  Central nervous system leukemia

          -  Uncontrolled systemic infection

          -  Uncompensated disseminated intravascular coagulation

          -  Symptomatic neuropathy of grade 2 or worse

          -  Known allergy to imidazole drugs.
Clinical trial NCT00620022 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol 300 μg, placebo
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults aged ≥ 40 years, who have signed an informed consent form prior
             to initiation of any study-related procedure.

          -  Co-operative outpatients with a diagnosis of moderate to severe chronic obstructive
             pulmonary disease (COPD), as classified by the GOLD Guidelines (2006), and:

               -  Smoking history of at least 20 pack years.

               -  Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥ 30%
                  of the predicted normal value.

               -  Post-bronchodilator FEV1/forced vital capacity (FVC) < 70%.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential.

          -  Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to
             screening or during the run-in period.

          -  Patients requiring oxygen therapy or who experience oxygen desaturation to < 80%
             during cycle exercise on room air.

          -  Patients with a Wmax value < 20 W (as determined by the incremental cycle endurance
             test) at screening.

          -  Patients who have had a respiratory tract infection within 6 weeks prior to screening.

          -  Patients with contra-indications of cardiopulmonary exercise testing.

          -  Patients with concomitant pulmonary disease.

          -  Patients with a history (up to and including the screening visit) of asthma.

          -  Patients with diabetes Type I or uncontrolled diabetes Type II.

          -  Any patient with lung cancer or a history of lung cancer.

          -  Any patient with active cancer or a history of cancer with less than 5 years disease
             free survival time.

          -  Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured
             at the collection of informed consent visit (Visit 1) or randomization is prolonged.

          -  Patients who have been vaccinated with live attenuated vaccines within 30 days prior
             to screening or during the run-in period.

          -  Patients unable to successfully use a dry powder inhaler device, metered dose inhaler
             (MDI), or perform spirometry measurements.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT01306214 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2, obesity
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: placebo, placebo, placebo, placebo, bi 10773, bi 10773
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of T2DM prior to informed consent

          2. Male and female patients on diet and exercise regimen who are pre-treated with
             multiple daily injections (MDI) of insulin alone or in combination with immediate or
             extended release metformin

          3. Stable metformin therapy: daily dose >=1500 mg/day or maximum tolerated dose

          4. HbA1c >=7.5% and <=10% at screening

        Exclusion criteria:

          1. Uncontrolled hyperglycemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an
             overnight fast during placebo run-in

          2. Any contraindications to metformin according to the local label

          3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent
Clinical trial NCT00295633 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin, saxagliptin, placebo, pioglitazone, rosiglitazone, metformin
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetics currently receiving a stable dose of TZD monotherapy (pioglitazone
             30mg or 45mg, or rosiglitazone 4mg or 8mg) for at least 12 weeks prior to screening.

          -  Hemoglobin A1c (HbA1c) > = 7.0% and < = 10.5%

          -  Body mass index < = 45kg/m2

          -  Fasting C-peptide > = 1 ng/mL

        Exclusion Criteria:

          -  Symptomatic poorly controlled diabetes

          -  Recent cardiac or cerebrovascular event

          -  Serum creatinine > = 2.0 mg/dL
Clinical trial NCT01545388 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin, metformin, metformin, placebo
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus (T2DM)

          -  Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 4
             weeks, on any additional oral hypoglycemic agent (AHA) in the prior 8 weeks, and HbA1c
             ≥ 6.0% and ≤ 9.0%; or

          -  Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 10
             weeks, not on any additional oral AHA in the prior 8 weeks, and HbA1c ≥ 6.5% and <
             10.0%

        Exclusion Criteria:

          -  Type 1 diabetes mellitus,

          -  Secondary diabetes mellitus, or

          -  Gestational diabetes mellitus
Clinical trial NCT01480284 (phase 3, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: gsk548470 300 mg tablet, etv 0.5 mg capsule
SMILES: NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C
Eligibility criteria:

        Inclusion Criteria:

          -  The ability to understand and sign a written informed consent form

          -  16 to 69 years of age at the time of informed consent

          -  Females of childbearing potential must have a negative pregnancy test and agree to
             avoidance of pregnancy

          -  Subject must show QTc < 450 millisecond (msec) or < 480 msec with Bundle Branch Block

          -  Chronic HBV infection, defined as positive serum HBsAg for at least 6 month, or
             negative serum IgM-HBc antibody

          -  HBeAg positive; HBV-DNA >= 6 log10 copies/mL, HBeAg negative; HBV-DNA >= 5 log10
             copies/mL

          -  Serum ALT >= 31 U/L and <= 10 × ULN

          -  Creatinine clearance >= 70 mL/min

          -  Haemoglobin >= 8 g/dL

          -  WBC >= 1,000 /mm3

          -  Nucleic acid analogue naïve, i.e., no prior therapy for over 6 months in the past

          -  No mutation that shows resistance in LAM, ETV and/or TDF at screening

        Exclusion Criteria:

          -  Decompensated liver disease

          -  Co-infection with HIV or HCV

          -  Autoimmune hepatitis rather than chronic hepatitis B

          -  Subject with serious complication

          -  Received or have a plan for solid organ or bone marrow transplantation

          -  Has proximal tubulopathy

          -  History of hypersensitivity to nucleoside and/or nucleotide analogues

          -  Evidence of hepatocellular carcinoma by diagnostic imaging at screening and/or serum
             α-fetoprotein > 50 ng/mL at screening

          -  History of HCC

          -  Received any nucleoside, nucleotide, interferon or HB vaccine therapy within 24 weeks
             prior to initiation

          -  Received overdose NSAIDs, excluding temporary or topical use, within 7 days prior to
             initiation

          -  Received drugs for injection containing glycyrrhizin as the main component within 4
             weeks prior to initiation

          -  Received drugs causing renal impairment, competitors of renal excretion,
             immunosuppressants, chemotherapeutics and/or corticosteroids within 8 weeks prior to
             initiation

          -  Participation in another clinical study within 6 months of study entry or planned
             participation in another clinical study after entry to this study

          -  Woman who is pregnant, lactating, possibly pregnant or planning a pregnancy during the
             study period

          -  Psychiatry disorder or cognitive disorder that may affect the subject ability to give
             informed consent or to follow specified study procedures

          -  History of alcohol or drug abuse

          -  Any condition or situation that may interfere with the subject's participation in the
             study